Loading…
S. 1097119th CongressOn the floor calendarLatest action Apr 10, 2025Decoded by AI · checked against the record
Official title: Interagency Patent Coordination and Improvement Act of 2025
Introduced:
Read the official bill on Congress.govThe plain-language version leads. The official text is always the reference.
S 1097 creates a USPTO-FDA task force to share drug patent and approval data with confidentiality protections.
35-second read · 4 questions answered below
The bill creates a formal task force linking USPTO and FDA to share information on prescription drug and biological product patents, including drug approvals, label changes, and scientific developments. It requires confidentiality protections, including 30 days' notice to companies before certain information is shared, and requires USPTO to report to Congress within four years on the program's effectiveness.
Pharmaceutical and biotech companies filing both FDA and patent applications, patent examiners reviewing drug-related patents, and potentially consumers and generic drug makers affected by patent exclusivity timing.
More thorough cross-checking between agencies could change how patent applications are evaluated and how long brand-name drugs retain exclusive market rights before generics can enter.
AI-drafted summary. Verify it against the official text before you act on it. Read the official bill on Congress.gov
Right now: it's on the Senate floor calendar. If the House changes it, it goes back to the Senate before reaching the President.
Latest action: — Placed on Senate Legislative Calendar under General Orders. Calendar No. 41.